Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction. In these patients, currently available OACs are contra-indicated or inadequate. Tecarfarin, a potentially best-in-class OAC, was designed to avoid cytochrome P450 (CYP) related metabolism that is a major cause of safety and efficacy problems related to the use of warfarin (Coumadin®), the current standard of care. In a recently completed phase 3 pivotal clinical trial (EMBRACE-AC), tecarfarin was shown to be safe and effective as an OAC in patients with prosthetic heart valves in addition to those with other conditions such as atrial fibrillation or venous thromboembolism, independent of their CYP status.
"Anti-coagulation is challenging in patients with prosthetic heart valves, where non-monitored oral anti-coagulation therapies are not indicated, and where a safe and effective alternative to warfarin would address an important clinical burden," commented Lord Ajay Kakkar , Professor of Surgery, University College London, England.
In December 2012, following a number of fatalities, the FDA informed health care professionals and the public that the novel non-monitored OAC which directly inhibits thrombin should not be used in patients with mechanical heart valves. Experts now recommend that none of the novel non-monitored OACs be used in patients with any type of prosthetic valves.
One of the major causes of unpredictable variability in warfarin anticoagulation response leading to bleeding complications or stroke is its metabolism by the enzyme, CYP2C9. This variability is further exacerbated if patients have a genetic variant of this enzyme.
"Tecarfarin was specifically designed not to be metabolized by any CYP enzymes, which means it may require less monitoring than warfarin. Some monitoring, according to experts, may still be needed to ensure patient compliance. Data from EMBRACE-AC trial showed that tecarfarin is a more effective OAC than warfarin in patients with a CYP2C9 genetic variant taking at least one CYP2C9 inhibitor despite close monitoring," said Dr Peter Milner , Executive Chairman of Armetheon and partner at AshHill Pharmaceutical Investments. He added, "for approval of tecarfarin, we anticipate only one more pivotal clinical trial will be required which could be a 'real world', open label study involving about 2500 pre-defined patients."
Recent research indicates that patients with chronic renal dysfunction or failure have reduced or variable activity of CYP enzymes such as CYP2C9 and CYP3A4 as well as the transporter permeability glycoprotein (P-gp). This may explain warfarin's suboptimal performance in this patient population. Currently marketed novel non-monitored OACs (in particular, Factor Xa inhibitors) are eliminated via the kidney and most of them are metabolized via CYP3A4 enzymes in addition to interacting with the P-gp. This may explain the significant variability in anticoagulation response to the novel non-monitored OACs in patients with chronic renal dysfunction or failure.